...
首页> 外文期刊>Cellular Physiology and Biochemistry >Metformin-Induced Changes of the Coding Transcriptome and Non-Coding RNAs in the Livers of Non-Alcoholic Fatty Liver Disease Mice
【24h】

Metformin-Induced Changes of the Coding Transcriptome and Non-Coding RNAs in the Livers of Non-Alcoholic Fatty Liver Disease Mice

机译:二甲双胍诱导非酒精性脂肪性肝病小鼠肝脏转录组和非编码RNA的变化

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background/Aims Recent studies have suggested that changes in non-coding mRNA play a key role in the progression of non-alcoholic fatty liver disease (NAFLD). Metformin is now recommended and effective for the treatment of NAFLD. We hope the current analyses of the non-coding mRNA transcriptome will provide a better presentation of the potential roles of mRNAs and long non-coding RNAs (lncRNAs) that underlie NAFLD and metformin intervention. Methods The present study mainly analysed changes in the coding transcriptome and non-coding RNAs after the application of a five-week metformin intervention. Liver samples from three groups of mice were harvested for transcriptome profiling, which covered mRNA, lncRNA, microRNA (miRNA) and circular RNA (circRNA), using a microarray technique. Results A systematic alleviation of high-fat diet (HFD)-induced transcriptome alterations by metformin was observed. The metformin treatment largely reversed the correlations with diabetes-related pathways. Our analysis also suggested interaction networks between differentially expressed lncRNAs and known hepatic disease genes and interactions between circRNA and their disease-related miRNA partners. Eight HFD-responsive lncRNAs and three metformin-responsive lncRNAs were noted due to their widespread associations with disease genes. Moreover, seven miRNAs that interacted with multiple differentially expressed circRNAs were highlighted because they were likely to be associated with metabolic or liver diseases. Conclusions The present study identified novel changes in the coding transcriptome and non-coding RNAs in the livers of NAFLD mice after metformin treatment that might shed light on the underlying mechanism by which metformin impedes the progression of NAFLD.
机译:背景/目的最近的研究表明,非编码mRNA的变化在非酒精性脂肪肝疾病(NAFLD)的进展中起着关键作用。现在推荐使用二甲双胍,其对NAFLD的治疗有效。我们希望当前对非编码mRNA转录组的分析能够更好地介绍作为NAFLD和二甲双胍干预基础的mRNA和长非编码RNA(lncRNA)的潜在作用。方法本研究主要分析了应用五周二甲双胍干预后编码转录组和非编码RNA的变化。使用微阵列技术,收集来自三组小鼠的肝脏样品进行转录组分析,所述分析涵盖了mRNA,lncRNA,microRNA(miRNA)和环状RNA(circRNA)。结果观察到系统减轻了二甲双胍对高脂饮食(HFD)诱导的转录组改变的影响。二甲双胍治疗在很大程度上逆转了与糖尿病相关途径的相关性。我们的分析还提出了差异表达的lncRNA与已知肝病基因之间的相互作用网络,以及circRNA及其与疾病相关的miRNA伴侣之间的相互作用。由于它们与疾病基因的广泛关联,注意到了八个HFD响应lncRNA和三个二甲双胍响应lncRNA。此外,突出显示了与多个差异表达的circRNA相互作用的七个miRNA,因为它们可能与代谢或肝脏疾病有关。结论本研究确定了二甲双胍治疗后NAFLD小鼠肝脏中编码转录组和非编码RNA的新变化,这可能揭示了二甲双胍阻碍NAFLD进程的潜在机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号